Search research articles
Contact Us
Filters
Showing results (1-10 of 39) with videos related to
Page
of 4
Sort By:
Journal of Internal Medicine
|
March 21, 2009
Infectious agents and lymphoma development: molecular and clinical aspects
A J M Ferreri, I Ernberg, C Copie-Bergman
ESMO Open
|
July 16, 2021
How we treat primary central nervous system lymphoma
T Calimeri, S Steffanoni, F Gagliardi, et al.
Leukemia & Lymphoma
|
April 26, 2012
Rational administration schedule for high-dose methotrexate in patients with primary central nervous system lymphoma
M Joerger, A D R Huitema, G Illerhaus, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 4, 2015
High-dose clarithromycin is an active monotherapy for patients with relapsed/refractory extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT): the HD-K phase II trial
A J M Ferreri, M Sassone, B Kiesewetter, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 7, 2002
Primary brain CD30+ ALK1+ anaplastic large cell lymphoma ('ALKoma'): the first case with a combination of 'not common' variants
M Ponzoni, M R Terreni, F Ciceri, et al.
European Journal of Radiology
|
September 7, 2021
Quantitative muscle mass biomarkers are independent prognosis factors in primary central nervous system lymphoma: The role of L3-skeletal muscle index and temporal muscle thickness
R Leone, G Sferruzza, T Calimeri, et al.
British Journal of Cancer
|
February 4, 2010
Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial
M Joerger, A D R Huitema, S Krähenbühl, et al.
Annals of Hematology
|
November 9, 2002
Autoantibodies against a 72-kDa ductal cell membrane glycoprotein in a patient affected by Sjögren's syndrome and gastric MALT lymphoma
F Folli, L Perego, M Ponzoni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 3, 2010
Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG)
A Conconi, G Martinelli, A Lopez-Guillermo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 21, 2018
ESMO Consensus Conference on malignant lymphoma: management of 'ultra-high-risk' patients
M Hutchings, M Ladetto, C Buske, et al.
Page
of 4
Search research articles
Search
Showing results (1-10 of 39) with videos related to
Sort By:
Page
of 4
Journal of Internal Medicine
|
March 21, 2009
Infectious agents and lymphoma development: molecular and clinical aspects
A J M Ferreri, I Ernberg, C Copie-Bergman
ESMO Open
|
July 16, 2021
How we treat primary central nervous system lymphoma
T Calimeri, S Steffanoni, F Gagliardi, et al.
Leukemia & Lymphoma
|
April 26, 2012
Rational administration schedule for high-dose methotrexate in patients with primary central nervous system lymphoma
M Joerger, A D R Huitema, G Illerhaus, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 4, 2015
High-dose clarithromycin is an active monotherapy for patients with relapsed/refractory extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT): the HD-K phase II trial
A J M Ferreri, M Sassone, B Kiesewetter, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 7, 2002
Primary brain CD30+ ALK1+ anaplastic large cell lymphoma ('ALKoma'): the first case with a combination of 'not common' variants
M Ponzoni, M R Terreni, F Ciceri, et al.
European Journal of Radiology
|
September 7, 2021
Quantitative muscle mass biomarkers are independent prognosis factors in primary central nervous system lymphoma: The role of L3-skeletal muscle index and temporal muscle thickness
R Leone, G Sferruzza, T Calimeri, et al.
British Journal of Cancer
|
February 4, 2010
Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial
M Joerger, A D R Huitema, S Krähenbühl, et al.
Annals of Hematology
|
November 9, 2002
Autoantibodies against a 72-kDa ductal cell membrane glycoprotein in a patient affected by Sjögren's syndrome and gastric MALT lymphoma
F Folli, L Perego, M Ponzoni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 3, 2010
Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG)
A Conconi, G Martinelli, A Lopez-Guillermo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 21, 2018
ESMO Consensus Conference on malignant lymphoma: management of 'ultra-high-risk' patients
M Hutchings, M Ladetto, C Buske, et al.
Page
of 4